BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Guangzhou Bio-gene Technology Co.\, Ltd readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Guangzhou Bio-gene Technology Co.
 \, Ltd's drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06118788-2871@assetmemo.bio
DTSTAMP:20261121T011041Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:BG1805: Phase 1/2 readout est. (NCT06118788)
DESCRIPTION:BG1805\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Phase I Cl
 inical Study: BG1805 Injection in the Treatment of Relapsed or Refractory 
 Acute Myeloid Leukemia\nEstimated primary completion: March 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/bg1805#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06118788
URL:https://assetmemo.bio/drug/bg1805#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
